[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"C. R. Bard\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":172},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,69,96,118,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100355723","prophylactic-reinforcement-of-ventral-abdominal-incisions-trial-100355723",false,"NCT03911700","Prophylactic Reinforcement of Ventral Abdominal Incisions Trial","Prospective, Multi-Center, Open-Label, Randomized, Controlled Trial of Phasix™ Mesh to Prevent Incisional Hernia Subsequent to Open Midline Laparotomy","PREVENT","Inclusion Criteria:\n\n1. Must be ≥ 18 years of age\n2. Elective, open midline laparotomy ≥ 5 cm\n3. Willing and able to provide written informed consent\n4. Hernia risk equal to moderate or greater\n\nExclusion Criteria:\n\n1. Previous hernia repair\n2. Emergent surgery\n3. Creation of skin flaps is preplanned\n4. Preplanned 2nd surgery\n5. Active skin pathology\n6. Life expectancy less than 24 months\n7. Pregnant or planning to become pregnant\n8. Receiving a medication\u002Fmedical condition that may adversely affect wound healing\n9. ASA Class \\> IV\n10. Enrolled in another clinical trial\n11. Site personnel directly involved with this trial\n12. Any condition that would preclude the use of the device or the subject form completing the follow-up requirements\n13. Known or suspected allergy to tetracycline hydrochloride or kanamycin sulfate\n14. Two separate incisions are created\n15. Prior onlay mesh\n16. Surgeon is unable to fully close the fascia\n17. The surgery requires more than a single piece of mesh\n18. Contraindication to placement of mesh\n19. CDC Class IV\u002FActive Infection\n20. Breastfeeding","ALL","18 Years",{"count":20,"type":21},477,"ESTIMATED","INTERVENTIONAL",[24],"NA","This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery.",[27],"Open Midline Laparotomy","RECRUITING","2026-06-10",{"date":31,"type":32},"2026-06-12","ACTUAL",{"date":34,"type":32},"2019-12-12",{"date":36,"type":21},"2031-12",{"name":38,"class":39},"C. R. Bard","INDUSTRY",45,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100511890","study-of-galaflex-lite-scaffold-in-treatment-of-capsular-contracture-after-breast-implant-augmentation-100511890","NCT05945329","Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmentation","A Prospective, Randomized, Controlled, Multi-Center Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmentation","STANCE","Inclusion Criteria:\n\n1. Genetically female ≥22 and ≤70 years of age;\n2. Breast augmentation subject with capsular contracture (Baker grade III or IV);\n3. Desires a new silicone implant with no more than a ± 150cc volume change in implant size;\n4. Planned revision approach via inframammary fold (IMF) incision;\n5. Willing and able to comply with the study procedures including the 2-year follow-up visit;\n6. Can complete all required study visits as scheduled (i.e., physically attend);\n7. Has reviewed and completed an FDA required Breast Implant Patient Decision Checklist (e.g., implant-specific provided by the manufacturer);\n8. Has compatible smart technology that can be used for downloading\u002Fusing the electronic patient diary; and,\n9. Provision of signed and dated informed consent form.\n\nExclusion Criteria:\n\n1. BMI \\\u003C18 or \\>35\n2. Existing and\u002For replacement implant size \\> 800 cc\n3. Has an extra-capsular silicone breast implant rupture where silicone gel has leaked outside of the capsule) in breast(s) intended for treatment\n4. Has prior use of a matrix (synthetic or biologic) in the breast(s) intended for treatment\n5. Abnormal breast findings on imaging within 1-year prior to randomization that have not been determined to be benign\n6. Subject reported current, or prior history of, Systemic Symptoms Associated with Breast Implants (SSBI - formerly referred to as BII (Breast Implant Illness))\n7. Infection present in the study breast(s) (day of index procedure (surgery) exclusions)\n8. Current or recent breastfeeding (within 3-months of enrollment) or history of mastitis within the 6-months prior to enrollment\n9. Prior or current diagnosis of breast cancer\n10. Has a mass that was palpated and has not been determined benign via acceptable imaging (MRI) or biopsy results\n11. Has undergone prior chest radiation treatment\n12. Has received chemotherapy within the last 12 months\n13. Current or recent (within 1-year of enrollment) alcohol\u002Fsubstance abuse\n14. Current or recent (within 4-weeks of enrollment) nicotine user (includes cigarettes, vaping, patches, gum, etc.)\n15. History of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIAALCL) or Breast Implant Associated Squamous Cell Carcinoma (BIA-SCC)\n16. Planned use of any other matrix (synthetic, biosynthetic, or biological) in the study breast(s) other than the GalaFLEX LITE™ Scaffold used to fully wrap the implant\n17. Planned (within the 2-year follow-up time period) use of medical (e.g. montelukast\u002FSingulair; zafirlukast\u002FAccolate), physical (e.g. massage), or device assisted (e.g. mechanical\u002Fthermal ultrasound) tools to manage the breast capsule(s)\n18. Any medical condition that, in the opinion of the investigator, may be associated with unduly high risk of intra- or post-operative complications (e.g., insulin dependent diabetes, autoimmune disease, connective tissue disorder, chronic lung or severe cardiovascular disease)\n19. Concurrent or planned use (within the 2-year follow-up time period) of autologous fat transfer in the study breast(s)\n20. Planned (within the 2-year follow-up time period) elective cosmetic surgery on the study breast(s) (e.g., staged mastopexy; revision for implant size change)\n21. Currently enrolled or has plans to enroll in another interventional clinical study that would interfere with this study\n22. Is pregnant or plans to become pregnant during the study period\n23. Known allergy to tetracycline hydrochloride and\u002For kanamycin sulfate\n24. Any condition that, in the Investigator's opinion, would preclude the use of the study device, interfere with the evaluation of the device or breast related outcomes\n25. Subject will not remain under the care of the investigator for all breast related plastic surgery procedures while enrolled in the study\n26. Actively using immunosuppressants such as oral steroids or biological therapies (inhalers or topical steroids are permitted)\n27. Confirmed diagnosis of the following rheumatic diseases or syndromes: systemic lupus erythematosus, Sjorgren's syndrome, scleroderma, polymyositis, or any connective tissue disorder, rheumatoid arthritis, crystalline arthritis, infectious arthritis, spondyloarthropathies, any other inflammatory arthritis, fibromyalgia, or chronic fatigue syndrome\n28. Has, in the investigator's opinion, a mental illness or disability that would preclude their participation in the study\n29. Subject has an implant that was never commercially available in the United States\n30. Has been implanted with any silicone implant other than breast implants\n31. Is taking any drugs that would interfere with blood clotting or might result in elevated risk of significant postoperative complications (e.g., anticoagulants or antiplatelet medications such as Xarelto, Aspirin, or Eliquis. NSAIDs such as Celebrex, Ibuprofen, Meloxicam are not exclusionary).\n32. Works for Sponsor or any of their subsidiaries, the study surgeon, or is helping to conduct the study or are directly related to anyone that works for BD or any of their subsidiaries or the study surgeons\n33. Subjects planning to undergo significant weight loss utilizing surgical intervention or prescribed medication(s) (e.g., gastric bypass; gastric sleeve; GLP1 agonists). Subjects with stable weight after previous surgery or current GLP-1 agonists use are not excluded.\n\nDay of Index Procedure (Surgery) Exclusion Criteria\n\n1. Has an extra-capsular rupture (breast implant silicone gel has leaked outside of the capsule) in breast(s) intended for treatment\n2. Suspicions of cancer from intraoperative capsule appearance such as capsule masses (based on surgical opinion\u002Fvisual findings; does not require definitive pathology) inclusive of both BIA-ALCL and BIA-SCC; or,\n3. Presence of a systemic infection, infection at the surgical site, or infection anywhere in the body at the time of surgery.","FEMALE","22 Years","70 Years",{"count":53,"type":21},250,[24],"Prospective, randomized, controlled study to assess the safety and effectiveness of GalaFLEX LITE™ Scaffold in revision surgery for reduction of capsular contracture recurrence and\u002For malposition in implant-based breast augmentation patients versus patients undergoing conventional revision surgery with no supportive matrix or acellular dermal matrix (ADM). Subjects will be randomized 2:1 to receive either GalaFLEX LITE™ Scaffold or standard care (no ADM or matrix placement). This study is designed using an adaptive approach. The number of the treated breasts will range between 250 and 530.",[57,58,59],"Capsular Contracture Associated With Breast Implant","Capsular Contracture Grade III","Capsular Contracture Grade IV","2026-05-21",{"date":62,"type":32},"2026-05-22",{"date":64,"type":32},"2024-12-12",{"date":66,"type":21},"2029-02",{"name":38,"class":39},34,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":85,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100411237","post-market-surveillance-study-of-the-bd-wavelinq-endoavf-system-100411237","NCT04634916","Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System","A Prospective, Multi-Center Clinical Study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis","CONNECT-AV","Inclusion Criteria:\n\n1. Subject must be either male or non-pregnant female ≥ 18 years of age with an expected lifespan sufficient to allow for completion of all study procedures.\n2. Subject must voluntarily sign and date the Informed Consent Form (ICF) prior to collection of study data or performance of study procedures.\n3. Subject must be willing to comply with the protocol requirements, including clinical follow-up.\n4. Subjects who have established, non-reversible kidney failure, who are currently on dialysis at screening or are in immediate need (within 6 months of endoAVF creation) of dialysis.\n5. Target treatment vein diameter(s) for endoAVF creation ≥ 2.0 mm as measured via Duplex Ultrasound (DUS) or Venography.\n6. Target treatment artery diameter ≥ 2.0 mm as measured via Duplex Ultrasound (DUS) or Arteriogram.\n7. Subject has adequate collateral circulation to the hand, in the opinion of the Investigator.\n8. At least one superficial outflow vein diameter ≥ 2.5 mm and in communication with the target creation site via a proximal forearm perforating vein.\n\nExclusion Criteria:\n\n1. The subject is in a hypercoagulable state.\n2. The subject has known bleeding diathesis.\n3. The subject has insufficient cardiac output to support a native fistula in the opinion of the Investigator.\n4. Known history of active intravenous drug abuse.\n5. \"Planned\" major surgical procedure within 6 months following index procedure or major surgery within 30 days prior to index procedure.\n6. The subject has a known allergy or hypersensitivity to contrast media which cannot be adequately pre-medicated.\n7. The subject has known adverse effects to sedation and\u002For anesthesia which cannot be adequately pre-medicated.\n8. Evidence of active infection on the day of the index procedure (temperature of ≥ 38.0° Celsius and\u002F or WBC of ≥ 12,000 cells\u002F μL, if collected).\n9. The subject has another medical condition, which, in the opinion of the Investigator, may cause him\u002Fher to be non-compliant with the protocol, confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up.\n10. The subject is currently participating in an investigational drug or another device study that has not completed the study treatment or that clinically interferes with the study endpoints. Note: Studies requiring extended follow-up visits for products that were investigational, but have since become commercially available, are not considered investigational studies.\n11. The subject has central venous stenosis or central vein narrowing \\> 50% based on imaging on the same side as the planned endoAVF creation.\n12. Absence of a proximal forearm perforating vein feeding the target cannulation vein(s) from the target creation site via Duplex Ultrasound (DUS) or Venography.\n13. Occlusion or stenosis \\> 50% of target cannulation vein(s) such as cephalic, median cubital, basilic, etc. assessed via Duplex Ultrasound (DUS) or Venography.\n14. Significantly compromised venous or arterial flow in the treatment arm as determined by Investigator and Duplex Ultrasound (DUS) or Venography.\n15. Presence of significant calcification at the target endoAVF location that could potentially impact the effectiveness of endoAVF creation as determined by the Investigator.",{"count":78,"type":21},280,[24],"A prospective, single-arm, multi-center post-market surveillance study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis.",[82,83,84],"Kidney Disease, End-Stage","End-stage Renal Disease","Arteriovenous Fistula",[86],"EndoAVF","2026-03-25",{"date":89,"type":32},"2026-03-27",{"date":91,"type":32},"2021-03-26",{"date":93,"type":21},"2027-09",{"name":38,"class":39},17,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":4},"100587907","observational-study-of-tissuepatch-sf-in-prevention-of-air-leaks-following-lung-resection-100587907","NCT06934486","Observational Study of TissuePatch SF in Prevention of Air Leaks Following Lung Resection","A Multi-Centre Prospective, Non-Comparative, Open, Post-Marketing Surveillance Study to Obtain Clinical Outcome Data on the Use of Tissue Patch in the Prevention of Air Leaks Following Lung Resection","Inclusion Criteria:\n\n1. Is ≥18 and \\\u003C80 years of age\n2. Undergoing planned (not emergent) video-assisted thoracic surgery pulmonary resection\n3. Understands and is willing to comply with all study related procedures\n4. Has provided signed informed consent\n\nExclusion Criteria:\n\n1. Women who are pregnant or lactating or, if of childbearing potential, are unwilling to use birth control for 6-months following surgery\n2. Has severe congestive heart failure, pulmonary or renal failure, serious haematological disorder or significant liver disease\n3. Has previously undergone a pneumonectomy\n4. Has a bronchial fistula\n5. Has or is suspected of having an active infection at or near the planned surgical site\n6. Has a known allergy or sensitization to TissuePatch SF or its constituent components\n7. In the investigator's opinion, has a life expectancy of less than 12 months\n8. Has, in the investigator's opinion, any disease or condition, physical or psychological, that could interfere with the evaluation of TissuePatch SF or compliance with study procedures\n\nIntra-Operative Exclusion Criteria:\n\n1. \\>3 identified air leaks\n2. No air leaks Macchiarini Grade ≥1","80 Years",{"count":53,"type":21},"OBSERVATIONAL","Post-market, observational study to assess effectiveness of TissuePatch SF in managing\u002Fpreventing air leaks after lung resection.",[108],"Post-operative Air Leaks","NOT_YET_RECRUITING","2026-02-09",{"date":112,"type":32},"2026-02-10",{"date":114,"type":21},"2026-07-01",{"date":116,"type":21},"2028-02-01",{"name":38,"class":39},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":134,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},"100567562","effectiveness-and-safety-of-tips-stent-graft-in-the-treatment-of-cirrhosis-and-complications-of-portal-hypertension-100567562","NCT06669806","Effectiveness and Safety of TIPS Stent Graft in the Treatment of Cirrhosis and Complications of Portal Hypertension","A Prospective, Multi-Center, Single-Arm Clinical Study to Evaluate the Effectiveness and Safety of LIVERTYTM TIPS Stent Graft in the Treatment of Cirrhosis and Complications of Portal Hypertension","Inclusion Criteria:\n\n1. The subject who is 18 years old or above but 75 years old or below;\n2. The subject who is diagnosed with portal hypertension caused by liver cirrhosis with the history of gastrointestinal variceal bleeding or bleeding, hepatic hydrothorax, and refractory or recurrent ascites;\n3. The subject must have adequate functional hepatic reserve with a Model for End-Stage Liver Disease (MELD) Score of ≤13 or Child-Pugh Score of ≤18;\n4. The subject with platelet count≥ 20×10\\^9 \u002FL;\n5. Subjects or their guardians who can understand the content of the clinical trial, voluntarily participate in the clinical trial and sign the ICF and can complete the follow-up period according to the requirements of the clinical trial.\n\nExclusion Criteria:\n\n1. The subject who is pregnant or lactating or plan to get pregnant during the clinical trial;\n2. According to the judgment of investigator, the subject with main portal vein thrombosis which thrombus occupying \\>50% of the portal vein lumen and affecting postoperative hemodynamics;\n3. The subject who has received surgical or interventional treatment (such as TIPS, surgical shunt and retrograde transvenous obliteration (-RTO) for treatment of complications from portal hypertension. Note: The subject who have received -RTO for variceal bleeding at least 8 weeks before signing the informed consent form can be included in the clinical trial;\n4. The subject who needs to receive or have received splenectomy;\n5. The subject who has received or plan to receive liver transplantation;\n6. The subject who cannot have a shunt channel established in the liver parenchyma between the hepatic vein and the portal vein as determined by the investigators;\n7. The subject with extrahepatic or hepatic malignancies;\n8. The subject with Budd-Chiari syndrome and hepatic sinusoidal obstruction syndrome;\n9. The subject with congenital cystic dilatation of bile duct (Caroli disease) and obstructive dilation of biliary tract;\n10. The subject with polycystic liver disease;\n11. The subject with cavernous transformation of the portal vein;\n12. The subject with severe or refractory hepatic encephalopathy (Grade 2 or above according to the West Haven Criteria);\n13. The subject with a TBIL level higher than 51.3 μmol\u002FL (excluding the Patients with cholestatic cirrhosis);\n14. The subject with coagulation disorders (INR: \\>2.5);\n15. The subject with a systolic pressure lower than 80 mmHg;\n16. The subject with severe tricuspid regurgitation or congestive heart failure;\n17. The subject with myocardial infarction within the past 3 months;\n18. The subject with moderate to severe pulmonary arterial hypertension, or severe hepatopulmonary syndrome;\n19. The subject with uncontrolled systemic infection or inflammation;\n20. The subject with severe renal insufficiency (Scr level:\\>199.5 μmol\u002FL) or needing to receive dialysis;\n21. The subject known to be allergic to the contrast media or to the constituent materials of the TIPS covered segment;\n22. The subject with the history of epilepsy or mental illness or with cognitive impairment;\n23. The subject with the expected survival time of less than 1 year;\n24. The subject who is otherwise determined as ineligible for participation in this Study by investigators;\n25. The subject who is participating in any other unfinished drug or medical device clinical trials.","75 Years",{"count":127,"type":21},166,[24],"This Study is a prospective, multi-center, single-arm objective perform an criteria (OPC) study. A 12 months follow-up study on the patients who intend to receive the treatment of cirrhosis and complications of portal hypertension with the TIPS Stent Graft will be conducted. The primary evaluation endpoint of this Study is the stent patency at 6 months after treatment completion .",[131,132,133],"Portal Hypertension Related to Cirrhosis","Ascites Hepatic","Variceal Bleeding",[135,136,137],"Transjugular intrahepatic portosystemic shunt","TIPS stent","patency","2025-12-18",{"date":140,"type":32},"2025-12-19",{"date":142,"type":32},"2024-11-21",{"date":144,"type":21},"2027-01-01",{"name":38,"class":39},1,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":171},"100594227","real-world-registry-of-the-rotarextm-rotational-excisional-atherectomy-system-xtract-registry-100594227","NCT07016698","Real-World Registry of the Rotarex(TM) Rotational Excisional Atherectomy System (XTRACT Registry)","A Prospective, Multicenter, Single Arm, Real-World Registry Assessing the Clinical Use of the Rotarex(TM) Rotational Excisional Atherectomy System (XTRACT Registry)","Inclusion Criteria:\n\n1. Subject or legally authorized representative provides written informed consent using an Informed Consent Form (ICF) that is reviewed and approved by the IRB for the site.\n2. Subject is ≥22 years old at the time of signing the informed consent.\n3. Subject must have a lesion(s) in their infra-inguinal peripheral arteries that can be treated with the RotarexTM Rotational Excisional Atherectomy System according to Instructions For Use (IFU).\n4. Rutherford 2-5 for chronic limb ischemia and Rutherford I to IIb for acute limb ischemia.\n5. Target lesion can be crossed intra-luminally by guidewire.\n6. At least one patent native outflow artery to the foot, free from significant stenosis(≥50% stenosis as confirmed by angiography) (ChLI Cohort only, not applicable to ALI Cohort).\n\nExclusion Criteria:\n\n1. Subject is unable or unwilling to comply with follow-up procedures and visits.\n2. Subject has a target lesion in a vessel with less than 3 mm in diameter.\n3. Subject is participating in another device or drug clinical trial that interferes with this protocol and confounds results.\n4. Treatment plan includes use of a thrombectomy and\u002For atherectomy device other than RotarexTM Rotational Excisional Atherectomy System.\n5. Life expectancy is below 1 year.\n6. Pregnant, planning to become pregnant during the course of the study or nursing a child.",{"count":155,"type":21},600,[24],"The XTRACT Registry is a prospective, single arm multicenter study on the use of on the Rotarex(TM) Rotational Excisional Atherectomy System.",[159],"Peripheral Arterial Disease(PAD)",[161,162],"Rotarex","PAD","2025-12-12",{"date":165,"type":32},"2025-12-17",{"date":167,"type":32},"2025-09-29",{"date":169,"type":21},"2029-05-31",{"name":38,"class":39},2,""]